A 5-year-old boy who initially presented with ALL and relapsed 4 months later with AML was found to have an add(19) in the leukemia cells. FISH revealed that the add(19) was really a cryptic t(l2;l9)(p13.3;p13.3) interrupting E2A (TCF3). Nucleotide sequences of cloned genomic fragments with the E2A rearrangements revealed that the der(12) contained E2A joined to an intron of the NOLI (p120) gene. Reverse transcriptase (RT)-PCR of patient lymphoblast RNA showed expression of in-frame fusion cDNAs consisting of most of NOL1 fused to the 3 0 portion of E2A that encoded part of the second transcriptional activation domain and the DNA binding and protein dimerization motifs. The reciprocal der(19) E2A genomic rearrangements included 5 0 regions of E2A joined to an intron of the ZNF384 (NMP4, CIZ) gene, located approximately 450 kb centromeric to NOL1 on chromosome 12. RT-PCR showed expression of in-frame E2A-ZNF384 fusion cDNAs. To our knowledge, this is the second report of a chromosome translocation in leukemia resulting in two different gene fusions. This is the first report of expression of E2A fusion protein that includes the DNA binding and protein dimerization domains due to a more proximal break in E2A compared to those described previously.
Introduction
The chromosome 19p13.3 gene E2A (TCF3) is a common target of chromosome translocation in acute lymphoblastic leukemia (ALL). 1 The t(1;19)(q23;p13), which occurs in about 5% of children and adults with ALL, creates an E2A-PBX1 fusion gene on the der (19) . 2, 3 A rare t(17;19)(q21;p13) is detected in less than 1% of ALL cases and fuses E2A to HLF. 4, 5 The genomic breakpoints of these translocations occur in a restricted region of the E2A gene and create E2A-PBX1 and E2A-HLF chimeric transcription factors that have transforming properties in fibroblast and transgenic mouse assays. [6] [7] [8] [9] [10] [11] [12] E2A is also interrupted by a cryptic inversion of chromosome 19 and/or a t (19;19) that fuses E2A to the 19q13.4 gene FB1, although the functional consequences of this chromosomal abnormality are not fully understood. 13 Herein, we describe cloning of two new E2A fusion genes created by a cryptic t(12;19)(p13.3;p13.3) in a child who presented initially with ALL and a complex karyotype and had early relapse with lineage switch to acute myeloid leukemia (AML).
Materials and methods

Case report
A 5-year-old boy was diagnosed with ALL based on blasts with mixed L1 and L2 morphology that expressed HLA-DR, CD19, CD34 and TdT. Reverse transcriptase (RT)-PCR studies were positive for BCR-ABL fusion transcripts of the minor type that encode the p190 fusion protein. Dilution experiments suggested that approximately 1 of 100 cells contained BCR-ABL fusion (data not shown). Standard cytogenetic studies on the original marrow aspirate showed a very complicated karyotype that included what was originally described as an add(19)(p13.3) (Figure 1) . A Philadelphia chromosome was detected in 1 of 30 cells (Figures 2a and b) . These findings were supported by fluorescence in situ hybridization (FISH) studies with sensitive dual color BCR and ABL probes, which showed 0.9% BCR-ABL þ cells in the patient sample versus 0.2% in normal controls with a s.d. of 0.1% and range of 0-0.4% (n ¼ 17, total of 15 037 cells analyzed). Based on the molecular data, the Philadelphia chromosome was considered to be a clonal abnormality, even though it was detected in only one metaphase. Multiple samples obtained after the initial ALL diagnosis were negative for BCR-ABL fusion via RT-PCR and the Ph 1 by both standard cytogenetics and FISH. The patient was treated with standard ALL chemotherapy and achieved a complete hematologic and cytogenetic remission. Less than 4 months after diagnosis he presented with a white blood cell count of 154 500 per microliter with 84% blasts. The morphology of the blast cells was quite different than those from his initial presentation with very large monocytic appearing, vacuolated cells. Flow cytometry studies showed an immature cell population that homogeneously expressed CD13 and CD33, which was weakly CD14 þ and for CD34, HLA-DR, CD19 and CD7. Cytogenetic studies showed that the leukemia cells had the complex karyotype seen at initial diagnosis with clonal evolution, and there were identical immunoglobulin heavy chain gene rearrangements in the ALL at diagnosis and AML at relapse (data not shown). Based on these results, he was diagnosed with recurrent leukemia with a lineage switch from ALL to AML, M5b.
He was treated with AML type chemotherapy and attained an unstable remission. He then underwent an unrelated donor umbilical cord blood transplant, but experienced marrow and central nervous system relapse and died at day 32 post transplant.
Specimens
Cryopreserved samples of the patient's neoplastic cells were obtained for further studies from the leukemia cell bank of The Children's Hospital, Denver, Colorado, and analyzed under a research protocol approved by an Institutional Review Board.
Classical and molecular cytogenetics
Giemsa-banded cytogenetic studies were performed from unstimulated cultures of bone marrow and peripheral blood. Samples were prepared using a direct technique and overnight culture methods as described previously.
14 Cytogenetic results are described using the International System for Cytogenetic Nomenclature (ISCN, 1995) . 15 FISH studies were performed using commercial probes including MLL, TEL/AML1, PML/RARA, CBFb (16q22), RB1(13q14), 16q11.2 satellite II repetitive sequence (D16Z3), whole chromosome painting wcp19, subtelomeric probes 1qtel, 7qtel, 8qtel, 14qtel, 16qtel, 19ptel (all from Vysis Inc., Downer's Grove IL, USA) and BCR/ABL dual color probe (Ventana Inc., Tucson, AZ, USA). Manufacturer's protocols were followed, and images were processed using an Olympus (Melville, NY, USA) BX60 epifluorescence microscope, a cooled charged capture device camera (Photometrics, Tucson, AZ, USA) and imaging software (Oncor Inc., and PSI/AI, Santa Clara, CA, USA). Two color FISH to investigate for a potential E2A translocation was performed as described previously using cocktails of cosmids located immediately centromeric and telomeric to E2A at 19p13.3. 16 We also performed FISH with a single cosmid (R23667) that contains most of E2A including the regions in which all previously described E2A translocations occur. All cosmids used to analyze E2A were provided by Anne Olsen and the human chromosome 19 mapping group from Lawrence Livermore National Labs (Livermore, CA, USA).
Molecular analyses
High molecular weight DNA and total RNA were extracted using the standard techniques. RT-PCR was performed to amplify BCR-ABL fusion transcripts as described previously. 14, 17 Southern blot analyses to detect E2A gene rearrangements were Figure 1 Karyotype of the major clone from the relapse acute myeloid leukemia (AML) bone marrow. The karyotype of the initial leukemia was characterized after detailed fluorescence in situ hybridization (FISH) studies as 46,XY,add(1)(q32),t(9;16)(p21;q22),t(12;19)(p13.3;p13.3), t(13;14)(q14;q32) [21] /46,idem,del(4)(q22q2?5) [5] /46,XY,add(1)(q32),der(9)t(9;16)(p21;q22) t(9;22)(q34;q11.2),t(12;19)(p13.3;p13.3),t(13;14) (q14;q32),der(16)t(9;16)(p21;q22),der(22)t(9;22)(q34;q11.2)[1]/46,XY [3] . This figure shows the karyotype of the major clone from AML relapse characterized as 46,XY,add(1)(q32),add(7)(q33),t(9;16)(p21;q22), t(12;19)(p13.3;p13.3),t(13;14)(q14;q32) [19] . The boxed no. 7 homologues show the abnormality that is unique to the AML clone. The other abnormalities were also observed in the bone marrow at the initial diagnosis of acute lymphoblastic leukemia (ALL).
New E2A translocation in acute leukemia C-h Zhong et al performed as described previously using the pE47M cDNA probe located in the 3 0 portion of E2A 2 or a PCR-generated cDNA probe complementary to E2A nucleotides 268-876 (Figure 4a ). Oligonucleotide pairs used to detect new E2A fusion transcripts included p120ex14for (downstream): 5 0 -CAA TTCTATCCCTCAGTCCCAG-3 0 and E2Aex10rev (upstream):
Cloning of E2A genomic rearrangements
An EcoRI genomic library was constructed using the Lambda DASH II kit (Stratagene, San Diego, CA, USA). Approximately one million recombinant phage were screened with the 3 0 E2A cDNA probe pE47M; 18 positive clones were purified to homogeneity and the phage inserts were characterized by nucleotide sequence analysis as described previously. 4 To identify the der(19), the same library was rescreened with a 5 0 E2A probe (complementary to nucleotides 268-876 of E2A mRNA) with positive clones purified and characterized as above.
Results
Discovery of a novel E2A translocation
To further characterize the add(19)(p13.3) present in the major clone and all minor subclones at both ALL diagnosis and AML relapse, we performed FISH with a two-color split signal E2A probe cocktail that we developed (Figure 2c) . 16 Interphase FISH showed one fused signal and split green and red signals indicative of a balanced translocation within the B35 kb region that separates the probe cocktails and contains the bulk of the E2A gene. Metaphase FISH demonstrated that the centromeric cosmids were retained on the der(19) while the telomeric cosmids were translocated to the short (p) arm of the abnormal chromosome 12 termed a del(12)(p12p13) in the karyotype. Thus, this leukemia contains a cryptic t(12;19)(p13.3;p13.3) that interrupts E2A. To confirm independently that this translocation interrupted E2A, we performed metaphase FISH with cosmid R23667, which is located between the telomeric and centromeric probe cocktails and contains most of E2A. These studies showed signals on the normal 19, der (19) and der (12) indicating that this translocation occurred in the central portion of R23667 and interrupted E2A (Figure 2d ). E2A gene rearrangements were detected in EcoRI and BamHI digested DNA with both 3 0 and 5 0 E2A cDNA probes, confirming a translocation within E2A and the presence of both der (19) and der(12) chromosomes (data not shown). The abnormal E2A FISH and Southern blot findings were present at both the time of initial diagnosis with ALL and at subsequent relapse with AML.
Additional FISH experiments were performed using a commercially prepared TEL-AML1 probe cocktail and a 12p subtelomere probe (data not shown). The TEL gene is retained on the der (12) indicating that the chromosome 12 breakpoint is located telomeric to TEL and the flanking sequences present in the FISH probe. In contrast, the 12 pTel probe was translocated to the der (19) , further confirming the reciprocal nature of the translocation.
Cloning of NOL1-E2A genomic fusion
To characterize the E2A rearrangements further, we constructed a genomic library using EcoRI digested patient DNA and screened it with a 3 0 E2A cDNA probe (pE47M). Lambda clones were purified containing inserts corresponding in size to the rearranged fragments. The ends of the insert were sequenced and shown to correspond to E2A genomic sequences on one end and chromosome 12 genomic sequences on the other end. The chromosome 12 sequences were located within a gene termed NOL1 (nucleolar protein 1; also termed p120).
19 Detailed sequence analysis (GenBank accession no. EU159435) showed that there was a break in NOL1 intron 14 and E2A intron 9, predicting a chimeric protein with the first 14 (of 15) exons of NOL1 fused to the C terminus of E2A starting with exon 10 (Figure 3a) . Notably this E2A breakpoint occurs more 5 0 than other E2A breakpoints described previously. RT-PCR primers were designed and used to amplify NOL1-E2A fusion transcripts from RNA isolated from the patient (Figure 3b ). Sequencing of PCR products (GenBank accession no. EU155120) showed that they were derived from NOL1-E2A fusion transcripts (Figure 3c ) that are predicted to encode a chimeric protein with in-frame joining of NOL1 to E2A (Figure 3d ).
The der (19) contains E2A fused to a second chromosome 12 gene, ZNF384
Multiple attempts to amplify E2A-NOL1 fusion transcripts predicted to derive from the reciprocal der(19) chromosome were unsuccessful. We were surprised by these findings as der (19) E2A fusion transcripts are expressed in all other E2A translocations and our FISH and Southern blot results indicated that the der(19) was retained. To investigate this further, we screened the genomic library constructed from patient DNA with a 5 0 E2A probe (Figure 4a ). Clones were identified, purified and the ends sequenced (GenBank accession no. EU159436). These showed fusion of E2A to chromosome 12 with a break in the predicted region of E2A but the chromosome 12 breakpoint was located approximately 450 kb centromeric to NOL1 within a gene termed ZNF384 (zinc-finger protein 394) also termed nuclear matrix protein isoform 4 (NMP4) or cas interacting zinc-finger protein (CIZ) (Figure 4b) . 20, 21 RT-PCR of patient RNA showed amplification of transcripts of the predicted size (Figure 4c) . Sequencing of PCR products (GenBank accession no. EU155119) demonstrated that they were derived from E2A-ZNF384 fusion transcripts (Figure 4d ) that are predicted to encode a chimeric protein with in-frame fusion of E2A to the entire ZNF384 open reading frame (Figure 4e ).
Predicted structure of NOL1-E2A and E2A-ZNF384
The predicted structure of known E2A fusion proteins and the newly discovered NOL1-E2A and E2A-ZNF384 are shown in Figure 5 . E2A-ZNF384 is structurally similar to previously described E2A-PBX1 and E2A-HLF but contains less of the second E2A transcriptional activation domain (AD2). In contrast, NOL1-E2A includes most of NOL1 fused in frame to the C terminus of E2A, including part of AD2 and the basic-helix-loophelix (bHLH) DNA binding and protein dimerization domain. This region of E2A is not expressed in any of the previously described E2A fusion proteins generated by chromosome translocations.
Discussion
The leukemia we describe was very unusual and clinically aggressive, with lymphoid morphology and phenotype at initial diagnosis. Remission was obtained, but relapse with lineage switch to AML occurred less than 4 months following diagnosis. The cytogenetic and molecular studies clearly establish that the same clone was present at ALL diagnosis and AML relapse. The very complicated karyotype and the low level presence of a Ph þ subclone at initial diagnosis further illustrate the genomic instability of this leukemia.
FISH studies revealed that an abnormal chromosome 19 observed in the karyotype at all times during the clinical course of this patient was really a cryptic t(12;19)(p13.3;p13.3). We cloned NOL1-E2A and E2A-ZNF384 DNA rearrangements and confirmed expression of fusion transcripts that are predicted to encode in-frame chimeric proteins.
NOL1 is a highly conserved, 120-kDa, nucleolar-specific, RNA-binding protein expressed by cells early in the G 1 phase of the cell cycle and peaking during S-phase. 19 A wide variety of malignant tumors express higher levels of NOL1 as compared with normal, resting cells. 19, 22, 23 Overexpression of NOL1 was reported to transform NIH3T3 cells, which were able to grow rapidly in nude mice. However, direct involvement of NOL1 in human cancer has not been reported previously.
ZNF384 was identified independently as a novel ligand for the p130cas docking protein, an important component of the integrin receptor signaling pathway and as a nuclear matrix architectural transcription factor. 21, 25 Multiple different ZNF384 isoforms are expressed that encode proteins containing five to eight zinc-fingers. 21, 26 This gene was first shown to be involved in human cancer when it was discovered that the t(12;17)(p13;q11) and t(12;22)(p13;q12) translocations fused ZNF384 to the related EWSR1 (chromosome 22) or TAF15 (chromosome 17) genes in acute leukemias. 27 Both TAF15-ZNF384 and EWSR1-ZNF384 transformed NIH 3T3 cells, although transformation was not dependent on altered expression of known ZNF384 target genes. 27 In parallel to that observation, we reported E2A-ZNF384 fusion in abstract form. 28 Based on our description, Corveleyn et al.
29 generated E2A-ZNF384 constructs, demonstrated that they were able to transform 3T3 cells, and suggested that the key contribution of E2A to the fusion protein was its transactivation domain. This hypothesis was supported by finding that an artificial construct consisting of the VP16 transactivation domain fused to ZNF384 had similar transforming properties. 29 Recently, there have been several other reports of E2A-ZNF384 fusion in leukemia. La Starza et al. 30 demonstrated E2A-ZNF384 fusion via FISH in a 21-year-old male with ALL associated with what was described initially as a del (12) 31 to analyze specimens from 161 unselected children with ALL. They discovered one case with a cryptic t(12;19) involving E2A, and localized the 12p13 breakpoint to a 122 kb region that includes ZNF384 along with two other genes. 32 Thus, E2A-ZNF384 fusion is a recurrent abnormality in leukemia; however, neither of these reports described the molecular consequences of E2A-ZNF384 fusion, nor identified NOL1-E2A fusion, as described in detail in this study.
To our knowledge, this is only the second reported case of a chromosome translocation fusing different portions of a single gene to two different genes in leukemia. In one case of AML, an ins(10;11)(p12;q23q12) was shown to fuse the 5 0 portion of the 11q23 gene MLL to the 3 0 portion of the 10p12 gene AF10, while the 5 0 portion of AF10 was fused to HEAB at 11q12. 33 This translocation we describe is also unique because it leads to expression of NOL1-E2A cDNAs that include the 3 0 end of E2A, which encodes the bHLH DNA binding and protein dimerization motif. This portion New E2A translocation in acute leukemia C-h Zhong et al of E2A is not expressed in the other E2A translocations characterized to date.
